The therapy of recurrent ERα-positive breast cancer in premenopausal and postmenopausal women may include surgery of the primary or metastatic lesions, radiation, chemotherapy, and ER-targeted therapy, despite the minimized production of estrogen in the postmenopausal patient. Here, ESR1 is linked to breast carcinoma.